MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,026 Shares of CG Oncology, Inc. (NASDAQ:CGON)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CG Oncology, Inc. (NASDAQ:CGON) by 3.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 30,080 shares of the company’s stock after purchasing an additional 1,026 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in CG Oncology were worth $862,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in CG Oncology in the fourth quarter valued at $68,000. KLP Kapitalforvaltning AS bought a new position in shares of CG Oncology in the 4th quarter worth about $100,000. Federated Hermes Inc. bought a new position in shares of CG Oncology in the 4th quarter worth about $172,000. Meeder Asset Management Inc. acquired a new position in shares of CG Oncology in the 4th quarter valued at about $189,000. Finally, NEOS Investment Management LLC lifted its stake in shares of CG Oncology by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company’s stock valued at $239,000 after purchasing an additional 817 shares during the period. 26.56% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 7.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Scotiabank assumed coverage on CG Oncology in a research note on Wednesday, April 16th. They set a “sector perform” rating and a $23.00 target price for the company. Morgan Stanley reduced their price objective on shares of CG Oncology from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Royal Bank of Canada lifted their price objective on shares of CG Oncology from $66.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, April 29th. JPMorgan Chase & Co. assumed coverage on shares of CG Oncology in a research note on Friday, May 2nd. They set an “overweight” rating and a $41.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $58.22.

CG Oncology Stock Down 1.2%

Shares of NASDAQ:CGON opened at $25.44 on Tuesday. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $40.47. The stock’s 50 day moving average is $23.21 and its 200-day moving average is $27.56. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -16.85 and a beta of 1.08.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.53 million. Equities research analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.